Anti-RANTES antibodies
US8012474B2 · kind B2 · utility
2Cited by
11References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 4, 2008 |
| Grant date | Sep 6, 2011 |
| Priority date | — |
| Expiry date | Jul 7, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.